Advances in bone turnover markers

Area of Science:

• Orthopedics
• Endocrinology
• Geriatrics

Background:

• Bone fragility fractures pose significant global health and economic burdens.
• Current fracture prediction relies on bone mineral density and clinical risk factors, yet many fractures remain undiagnosed.
• There is a need for improved methods to identify individuals at high risk of bone fragility fractures.

Purpose of the Study:

• To investigate the potential of bone turnover markers (BTM) as novel factors for improving bone fragility fracture risk assessment.
• To evaluate the utility of BTM in conjunction with existing methods for a more comprehensive fracture risk calculation.

Main Methods:

• Review of current literature on bone mineral density, clinical risk factors, and bone turnover markers (BTM).
• Analysis of the physiological basis of BTM, including their origin from bone remodeling processes (osteoclast and osteoblast activity).
• Examination of factors influencing BTM levels and their impact on predictive accuracy.

Main Results:

• Bone turnover markers (BTM) are released during bone remodeling and can be measured in serum or urine.
• BTM reflect bone resorption and formation, offering a dynamic view of bone health.
• Physiologic and pathophysiologic factors can influence BTM, limiting their standalone predictive power.

Conclusions:

• While bone turnover markers (BTM) show promise for fracture risk assessment, their clinical utility is currently limited.
• Further research is needed to overcome the influencing factors affecting BTM and enhance their role in fracture prediction.
• The inclusion of BTM in clinical guidelines for fracture risk remains restricted due to these limitations.